{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:55:49Z","timestamp":1787626549502,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013806","name":"Shenyang Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejmech.2026.118913","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:27:27Z","timestamp":1777508847000},"page":"118913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A novel c-Met inhibitor containing chiral pyrrolidine side chain and its application as anti-tumor agents"],"prefix":"10.1016","volume":"314","author":[{"given":"Longcai","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puzhuang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-6200","authenticated-orcid":false,"given":"Xingshu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10512","key":"10.1016\/j.ejmech.2026.118913_bib1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(25)01635-6","article-title":"The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the global burden of disease study 2023","volume":"406","author":"Force","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118913_bib2","first-page":"171","article-title":"Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer","volume":"3","author":"Rath","year":"2020","journal-title":"Cancer Drug Resist."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118913_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118913_bib4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12885-024-11934-2","article-title":"Molecular alterations and clinical prognostic factors in resectable non-small cell lung cancer","volume":"24","author":"Thamrongjirapat","year":"2024","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118913_bib5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-021-01121-2","article-title":"Targeted therapy in advanced non-small cell lung cancer: current advances and future trends","volume":"14","author":"Majeed","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"44","key":"10.1016\/j.ejmech.2026.118913_bib6","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.18632\/oncotarget.27788","article-title":"MEK inhibitors in non-V600 BRAF mutations and fusions","volume":"11","author":"Johnson","year":"2020","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118913_bib7","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/0008-5472.CAN-04-2650","article-title":"Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer","volume":"65","author":"Ma","year":"2005","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118913_bib8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","article-title":"BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition","volume":"11","author":"Hofmann","year":"2021","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118913_bib9","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s10555-020-09903-9","article-title":"Current therapy of KRAS-mutant lung cancer","volume":"39","author":"Ghimessy","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2026.118913_bib10","doi-asserted-by":"crossref","first-page":"527750","DOI":"10.3389\/fimmu.2020.527750","article-title":"ROS1 fusion mediates immunogenicity by upregulation of PD-L1 after the activation of ROS1-SHP2 signaling pathway in non-small cell lung cancer","volume":"11","author":"Cai","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118913_bib11","series-title":"Extracellular Targeting of Cell Signaling in Cancer: Strategies Directed at MET and RON Receptor Tyrosine Kinase Pathways [M]","first-page":"199","author":"James","year":"2018"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118913_bib12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/genes14020517","article-title":"An introduction and overview of RON receptor tyrosine kinase signaling","volume":"14","author":"Hunt","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.ejmech.2026.118913_bib13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fcell.2020.00152","article-title":"Targeting the HGF\/MET axis in cancer therapy: challenges in resistance and opportunities for improvement","volume":"8","author":"Huang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2026.118913_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/bs.acr.2020.04.006","article-title":"MET receptor in oncology: from biomarker to therapeutic target","volume":"147","author":"Malik","year":"2020","journal-title":"Adv. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118913_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.118913_bib16","doi-asserted-by":"crossref","first-page":"155379","DOI":"10.1016\/j.phymed.2024.155379","article-title":"c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy","volume":"128","author":"Mohan","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2026.118913_bib17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2018.07.006","article-title":"Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - a systematic review and meta-analysis","volume":"123","author":"Vuong","year":"2018","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118913_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djw262","article-title":"Exon 14 deleted MET receptor as a new biomarker and target in cancers","volume":"109","author":"Cortot","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118913_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","article-title":"MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118913_bib20","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1007\/s00432-022-04225-5","article-title":"MET overexpression in EGFR L858R mutant treatment-na\u00efve advanced lung adenocarcinoma correlated with poor prognosis: a real-world retrospective study","volume":"149","author":"Wang","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118913_bib21","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/jcp.25794","article-title":"C-Met as a potential target for the treatment of gastrointestinal cancer: current status and future perspectives","volume":"232","author":"Bahrami","year":"2017","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118913_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41568-018-0002-y","article-title":"Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy","volume":"18","author":"Comoglio","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118913_bib23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2018.36.4_suppl.74","article-title":"MET-amplification (MET-amp) in relation to aggressive biology in esophagogastric cancer (EGC): an analysis of clinical outcomes of MET-amp vs non-MET-amp EGC","volume":"36","author":"Hong","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.ejmech.2026.118913_bib24","doi-asserted-by":"crossref","first-page":"9101","DOI":"10.3390\/ijms25169101","article-title":"Unveiling the role of HGF\/c-Met signaling in non-small cell lung cancer tumor microenvironment","volume":"25","author":"Yao","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"28","key":"10.1016\/j.ejmech.2026.118913_bib25","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1038\/s41388-021-01863-w","article-title":"HGF\/c-MET pathway in cancer: from molecular characterization to clinical evidence","volume":"40","author":"Fu","year":"2021","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118913_bib26","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","article-title":"Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcS\u00e9 phase II trial","volume":"30","author":"Moro-Sibilot","year":"2019","journal-title":"Ann. Oncol."},{"issue":"15","key":"10.1016\/j.ejmech.2026.118913_bib27","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1200\/JCO.2021.39.15_suppl.9020","article-title":"Capmatinib in MET exon 14-mutated, advanced NSCLC: updated results from the GEOMETRY mono-1 study","volume":"29","author":"Wolf","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118913_bib28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2022.10.030","article-title":"Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: results from the GEOMETRY mono-1 study","volume":"183","author":"Wolf","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118913_bib29","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET Exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118913_bib30","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","article-title":"Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b\/2, multicentre, randomised trial","volume":"8","author":"Wu","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118913_bib31","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/jjco\/hyab072","article-title":"Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: japanese subset analysis from the Phase II VISION study","volume":"51","author":"Sakai","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"10526","key":"10.1016\/j.ejmech.2026.118913_bib32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(25)01811-2","article-title":"Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial","volume":"407","author":"Lu","year":"2026","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118913_bib33","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1038\/s41467-021-24367-3","article-title":"Structural basis of the activation of c-MET receptor","volume":"12","author":"Uchikawa","year":"2021","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118913_bib34","first-page":"873","article-title":"Savolitinib induced pathological complete response in non-small cell lung cancer with MET amplification: a case report","volume":"27","author":"Lu","year":"2024","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"10.1016\/j.ejmech.2026.118913_bib35","first-page":"101952","article-title":"Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b\/2 trial","volume":"59","author":"Yu","year":"2023","journal-title":"Clin. Med."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118913_bib36","doi-asserted-by":"crossref","first-page":"CT034","DOI":"10.1158\/1538-7445.AM2022-CT034","article-title":"Abstract CT034: phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)","volume":"82","author":"Lu","year":"2022","journal-title":"Cancer Res."},{"issue":"31","key":"10.1016\/j.ejmech.2026.118913_bib37","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.23.02363","article-title":"Vebreltinib for advanced non-small cell lung cancer harboring c-Met Exon 14 skipping mutation: a multicenter, single-arm, Phase II KUNPENG study","volume":"42","author":"Yang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118913_bib38","article-title":"Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations","volume":"34","author":"Yang","year":"2023"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118913_bib39","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s12325-024-02799-9","article-title":"Clinical management of patients with non-small cell lung cancer, brain metastases, and actionable genomic alterations: a systematic literature review","volume":"41","author":"Khasraw","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2026.118913_bib40","doi-asserted-by":"crossref","first-page":"1717432","DOI":"10.3389\/fonc.2026.1717432","article-title":"Brain metastases from non-small cell lung cancer: molecular subtypes and emerging CNS-directed precision therapies","volume":"16","author":"Sharma","year":"2026","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118913_bib41","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41417-025-00916-6","article-title":"Blood-brain barrier alterations as an initiator of brain metastasis from lung cancer: a new take on an old story","volume":"32","author":"Wu","year":"2025","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ejmech.2026.118913_bib42","doi-asserted-by":"crossref","first-page":"1717244","DOI":"10.3389\/fonc.2026.1717244","article-title":"Association of regional specificity of blood-brain barrier permeability with pathological subtypes in cerebral white matter of patients with non-brain metastatic lung cancer","volume":"16","author":"Wang","year":"2026","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.118913_bib43","doi-asserted-by":"crossref","first-page":"1015011","DOI":"10.3389\/fonc.2022.1015011","article-title":"Blood-brain barrier and brain structural changes in lung cancer patients with non-brain metastases","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118913_bib44","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41571-021-00529-6","article-title":"The blood\u2013tumor barrier in cancer biology and therapy","volume":"18","author":"Steeg","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118913_bib45","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/ph16030339","article-title":"Asymmetric synthesis of US-FDA approved drugs over five years (2016-2020): a recapitulation of chirality","volume":"16","author":"Tamatam","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118913_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.51470\/APR.2024.03.02.07","article-title":"The role of chirality in drug design and delivery: a comprehensive review","volume":"3","author":"Aher","year":"2024","journal-title":"Acta. Pharma. Rep."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118913_bib47","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2174\/1570163816666190502101803","article-title":"Drug stereochemistry: a prodigy for pharmacology and drug development","volume":"17","author":"Gandhi","year":"2020","journal-title":"Curr. Drug Discov. Technol."},{"issue":"16_suppl","key":"10.1016\/j.ejmech.2026.118913_bib48","doi-asserted-by":"crossref","first-page":"8575","DOI":"10.1200\/JCO.2024.42.16_suppl.8575","article-title":"Health-related quality of life (HRQoL) with Tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal, or bone metastases in the phase II VISION trial","volume":"42","author":"Reinmuth","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118913_bib49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2021.11.020","article-title":"Brain penetration and efficacy of Tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases","volume":"163","author":"Friese-Hamim","year":"2022","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118913_bib50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/bdd.2345","article-title":"Recent advances in the in vitro and in vivo methods to assess impact of P-glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition","volume":"44","author":"Chatterjee","year":"2023","journal-title":"Biopharm Drug Dispos."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118913_bib51","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00280-022-04423-5","article-title":"Population pharmacokinetic analysis of Tepotinib, an oral MET kinase inhibitor, including data from the VISION study","volume":"89","author":"Xiong","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118913_bib52","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s10637-020-00926-1","article-title":"Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers","volume":"38","author":"Johne","year":"2020","journal-title":"Invest. N. Drugs"},{"issue":"21","key":"10.1016\/j.ejmech.2026.118913_bib53","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.3390\/molecules25215004","article-title":"Identification of iminium intermediates generation in the metabolism of Tepotinib using LC-MS\/MS: in silico and practical approaches to bioactivation pathway elucidation","volume":"25","author":"Abdelhameed","year":"2020","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118913_bib54","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/separations10060330","article-title":"An LC\u2013MS\/MS analytical method for quantifying Tepotinib in human liver microsomes: application to in vitro and in silico metabolic stability estimation","volume":"10","author":"Attwa","year":"2023","journal-title":"Separations"},{"issue":"27","key":"10.1016\/j.ejmech.2026.118913_bib55","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.2174\/0113816128314500240621071306","article-title":"Design, synthesis and evaluation of a novel Teoptinib derivative as an effective anti-hepatocellular carcinoma agent","volume":"30","author":"Yu","year":"2024","journal-title":"Curr. Pharm. Des."},{"issue":"22","key":"10.1016\/j.ejmech.2026.118913_bib56","doi-asserted-by":"crossref","first-page":"20022","DOI":"10.1021\/acs.jmedchem.4c01987","article-title":"Proline analogues in drug design: current trends and future prospects","volume":"67","author":"Kubyshkin","year":"2024","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118913_bib57","doi-asserted-by":"crossref","first-page":"7158","DOI":"10.1021\/acs.jmedchem.4c00021","article-title":"Development of prolinol containing inhibitors of hypoxanthine\u2013guanine\u2013xanthine phosphoribosyltransferase: rational structure-based drug design","volume":"67","author":"Keough","year":"2024","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118913_bib58","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s41061-021-00347-5","article-title":"Pyrrolidine in drug discovery: a versatile scaffold for novel biologically active compounds","volume":"379","author":"Li","year":"2021","journal-title":"Top. Curr. Chem."},{"key":"10.1016\/j.ejmech.2026.118913_bib59","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s10593-025-03405-8","article-title":"Synthesis of chiral pyrrolidine derivatives with promising pharmacological activity","volume":"61","author":"Yeganyan","year":"2025","journal-title":"Chem. Heterocycl. Compd."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118913_bib60","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41573-023-00703-8","article-title":"Deuterium in drug discovery: progress, opportunities and challenges","volume":"22","author":"Di Martino","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118913_bib61","doi-asserted-by":"crossref","first-page":"106490","DOI":"10.1016\/j.bioorg.2023.106490","article-title":"Deuterated driven new chemical entities: an optimistic way to improve therapeutic efficacy","volume":"135","author":"Chandra Mouli","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118913_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cmdc.202400836","article-title":"The Application of deuteration strategy in drug design","volume":"20","author":"Chen","year":"2025","journal-title":"ChemMedChem"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118913_bib63","first-page":"449","article-title":"Deuterium in pharmacology [J\/OL]. Anales de la Real Academia Nacional de Farmacia","volume":"90","author":"Cu\u00e9llar Rodr\u00edguez","year":"2025"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118913_bib64","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1021\/acs.jmedchem.8b01808","article-title":"Applications of deuterium in medicinal chemistry","volume":"62","author":"Pirali","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118913_bib65","series-title":"2-(2,4,5-substituted Aniline) Pyrimidine Derivative, Pharmaceutical Composition and Use Thereof","author":"Zhu","year":"2019"},{"issue":"15","key":"10.1016\/j.ejmech.2026.118913_bib66","doi-asserted-by":"crossref","first-page":"12835","DOI":"10.1021\/acs.jmedchem.4c00796","article-title":"Deuterium editing of small molecules: a case study on antitumor activity of 1,4-benzodiazepine-2,5-dione derivatives","volume":"67","author":"Yu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118913_bib67","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s12012-019-09559-0","article-title":"How the deuteration of dronedarone can modify its cardiovascular profile: in vivo characterization of electropharmacological effects of poyendarone, a deuterated analogue of dronedarone","volume":"20","author":"Kambayashi","year":"2020","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.ejmech.2026.118913_bib68","doi-asserted-by":"crossref","first-page":"112774","DOI":"10.1016\/j.fct.2021.112774","article-title":"Pharmacokinetic, pharmacological, and genotoxic evaluation of deuterated caffeine","volume":"160","author":"Parente","year":"2022","journal-title":"Food Chem. Toxicol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118913_bib69","doi-asserted-by":"crossref","first-page":"e0154002","DOI":"10.1371\/journal.pone.0154002","article-title":"The quantum nature of drug-receptor interactions: deuteration changes binding affinities for histamine receptor ligands","volume":"11","author":"Kr\u017ean","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118913_bib70","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1021\/jm1010995","article-title":"Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure","volume":"54","author":"Kerekes","year":"2010","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118913_bib71","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.bmcl.2015.02.002","article-title":"Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors","volume":"25","author":"Dorsch","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:07:05Z","timestamp":1783148825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426003582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":71,"alternative-id":["S0223523426003582"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118913","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel c-Met inhibitor containing chiral pyrrolidine side chain and its application as anti-tumor agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118913"}}